<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease - Teo, E - 2017 | Cochrane Library</title> <meta content="Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease - Teo, E - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010010.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease - Teo, E - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010010.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010010.pub3" name="dc.identifier" scheme="DOI"/> <meta content="&lt;i&gt;Haemophilus influenzae&lt;/i&gt; oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Edward Teo" name="citation_author"/> <meta content="eteo@outlook.com" name="citation_author_email"/> <meta content="Kathleen Lockhart" name="citation_author"/> <meta content="Townsville Hospital" name="citation_author_institution"/> <meta content="Sai Navya Purchuri" name="citation_author"/> <meta content="Logan Hospital" name="citation_author_institution"/> <meta content="Jennifer Pushparajah" name="citation_author"/> <meta content="Waitakere Hospital" name="citation_author_institution"/> <meta content="Allan W Cripps" name="citation_author"/> <meta content="Griffith University" name="citation_author_institution"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD010010.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010010.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010010.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010010.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anti‐Bacterial Agents [administration &amp; dosage]; Bronchitis, Chronic [mortality, *prevention &amp; control]; Disease Progression; Haemophilus Vaccines [*administration &amp; dosage]; Haemophilus influenzae [*immunology]; Pulmonary Disease, Chronic Obstructive [mortality, *prevention &amp; control]; Randomized Controlled Trials as Topic; Secondary Prevention; Tablets, Enteric‐Coated" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010010.pub3&amp;doi=10.1002/14651858.CD010010.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010010\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010010\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010010.pub3",title:"\u003ci\u003eHaemophilus influenzae\u003c/i\u003e oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease",firstPublishedDate:"Jun 19, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010010.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010010.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010010.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010010.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010010.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010010.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010010.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010010.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010010.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010010.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2049 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010010.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-sec-0074"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/appendices#CD010010-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/table_n/CD010010StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/table_n/CD010010StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en"><i>Haemophilus influenzae</i> oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#CD010010-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Edward Teo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#CD010010-cr-0003">Kathleen Lockhart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#CD010010-cr-0004">Sai Navya Purchuri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#CD010010-cr-0005">Jennifer Pushparajah</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#CD010010-cr-0006">Allan W Cripps</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information#CD010010-cr-0007">Mieke L van Driel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information/en#CD010010-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010010.pub3">https://doi.org/10.1002/14651858.CD010010.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010010-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010010-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010010-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010010-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010010-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010010-abs-0001" lang="en"> <section id="CD010010-sec-0001"> <h3 class="title" id="CD010010-sec-0001">Background</h3> <p>Chronic bronchitis and chronic obstructive pulmonary disease (COPD) are serious conditions in which patients are predisposed to viral and bacterial infections resulting in potentially fatal acute exacerbations. Chronic obstructive pulmonary disease is defined as a lung disease characterised by obstruction to lung airflow that interferes with normal breathing. Antibiotic therapy has not been particularly useful in eradicating bacteria such as non‐typeable <i>Haemophilus influenzae</i> (NTHi) because they are naturally occurring flora of the upper respiratory tract in many people. However, they can cause opportunistic infection. An oral NTHi vaccine has been developed to protect against recurrent infective acute exacerbations in chronic bronchitis. </p> </section> <section id="CD010010-sec-0002"> <h3 class="title" id="CD010010-sec-0002">Objectives</h3> <p>To assess the effectiveness of an oral, whole‐cell NTHi vaccine in protecting against recurrent episodes of acute exacerbations of chronic bronchitis and COPD in adults. To assess the effectiveness of NTHi vaccine in reducing NTHi colonising the respiratory tract during recurrent episodes of acute exacerbations of COPD. </p> </section> <section id="CD010010-sec-0003"> <h3 class="title" id="CD010010-sec-0003">Search methods</h3> <p>We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 1), MEDLINE (1946 to January 2017), Embase (1974 to January 2017), CINAHL (1981 to January 2017), LILACS (1985 to January 2017), and Web of Science (1955 to January 2017). We also searched trials registries and contacted authors of trials requesting unpublished data. </p> </section> <section id="CD010010-sec-0004"> <h3 class="title" id="CD010010-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing the effects of an oral monobacterial NTHi vaccine in adults with recurrent acute exacerbations of chronic bronchitis or COPD when there was overt matching of the vaccine and placebo groups on clinical grounds. The selection criteria considered populations aged less than 65 years and those older than 65 years. </p> </section> <section id="CD010010-sec-0005"> <h3 class="title" id="CD010010-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data from original records and publications for incidence and severity of bronchitis episodes and carriage rate of NTHi measured in the upper respiratory tract, as well as data relevant to other primary and secondary outcomes. </p> </section> <section id="CD010010-sec-0006"> <h3 class="title" id="CD010010-sec-0006">Main results</h3> <p>We identified six placebo‐controlled randomised controlled trials with a total of 557 participants. These trials investigated the efficacy of enteric‐coated, killed preparations of <i>H influenzae</i> in populations prone to recurrent acute exacerbations of chronic bronchitis or COPD. The vaccine preparation and immunisation regimen in all trials consisted of at least three courses of formalin‐killed <i>H influenzae</i> in enteric‐coated tablets taken at intervals (e.g. days 0, 28, and 56). Each course generally consisted of two tablets taken after breakfast over three consecutive days. In all cases the placebo groups took enteric‐coated tablets containing glucose. Risk of bias was moderate across the studies, namely due to the lack of information provided about methods and inadequate presentation of results. </p> <p>Meta‐analysis of the oral NTHi vaccine showed a small, non‐statistically significant reduction in the incidence of acute exacerbations of chronic bronchitis or COPD (risk ratio (RR) 0.79, 95% confidence interval (CI) 0.57 to 1.10; P = 0.16). There was no significant difference in mortality rate between the vaccine and placebo groups (odds ratio (OR) 1.62, 95% CI 0.63 to 4.12; P = 0.31). </p> <p>We were unable to meta‐analyse the carriage levels of NTHi in participants as each trial reported this result using different units and tools of measurement. Four trials showed no significant difference in carriage levels, while two trials showed a significant decrease in carriage levels in the vaccinated group compared with the placebo group. </p> <p>Four trials assessed severity of exacerbations measured by requirement for antibiotics. Three of these trials were comparable and when meta‐analysed showed a statistically significant 80% increase in antibiotic courses per person in the placebo group (RR 1.81, 95% CI 1.35 to 2.44; P &lt; 0.001). There was no significant difference between the groups with regard to hospital admission rates (OR 0.96, 95% CI 0.13 to 7.04; P = 0.97). Adverse events were reported in five trials but were not necessarily related to the vaccine; a point estimate is suggestive that they occurred more frequently in the vaccine group, however this result was not statistically significant (RR 1.43, 95% CI 0.70 to 2.92; P = 0.87). Quality of life was not meta‐analysed but was reported in two trials, with results at six months showing an improvement in quality of life in the vaccinated group (scoring at least two points better than placebo). </p> </section> <section id="CD010010-sec-0007"> <h3 class="title" id="CD010010-sec-0007">Authors' conclusions</h3> <p>Analyses demonstrate that NTHi oral vaccination of people with recurrent exacerbations of chronic bronchitis or COPD does not yield a significant reduction in the number and severity of exacerbations. Evidence was mixed, and the individual trials that showed a significant benefit of the vaccine are too small to advocate widespread oral vaccination of people with COPD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010010-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010010-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010010-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010010-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010010-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010010-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010010-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010010-abs-0003" lang="en"> <h3>Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of a non‐typeable <i>Haemophilus influenzae</i> (NTHi) vaccine in preventing repeated <i>H influenzae</i> infections in people with chronic obstructive pulmonary disease (COPD) or chronic bronchitis. </p> <p><b>Background</b> </p> <p>People with COPD can have frequent infections that worsen symptoms of their lung disease, that is increased breathlessness, purulent discharge and decompensating oxygen saturations levels, known as an 'acute exacerbation'. The bacteria that most commonly causes this is <i>H influenzae.</i> Infection with <i>H influenzae</i> can lead to hospitalisation, and in some cases, death. Preventing these infections with a vaccine could lead to people with COPD having improved outcomes compared to the current practice of treating infections as they arise. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to January 2017. We identified six studies with a total of 557 participants. The studies were blinded, placebo‐controlled randomised trials that tested how effective the NTHi vaccine is in preventing infections in people over 18 years of age with COPD or chronic bronchitis. In all six trials, both the vaccine and placebo group were given at least three courses of tablets at regular intervals over a period of three to 12 months. Generally, the baseline demographics of participants across the included studies shared similar characteristics (such as diet, lifestyle, and living conditions) to other high‐income countries. Ages ranged between 40 and 80 years. The studies counted the number of infections the participants experienced, levels of respiratory tract bacteria, deaths, side effects, hospital admissions, or treatment with antibiotics. </p> <p><b>Key results</b> </p> <p>The NTHi vaccine had no significant impact on reducing the number of acute exacerbations experienced by people with COPD. There was no significant difference in mortality rate between the vaccine and placebo groups, and the reported deaths in the vaccinated group were not attributed to the vaccine. </p> <p>The levels of <i>H influenzae</i> bacteria found in the respiratory tracts of participants did not differ between the vaccine and placebo groups. Due to inconsistencies of measurement between the trials, we were not able to compare the studies against one another. </p> <p>Antibiotics, which can be an indicator of severe infection, were significantly more commonly prescribed in the placebo group. Evidence of hospital admissions showed that there was no difference in the likelihood of being hospitalised in either the vaccine or the placebo group. Two trials studying quality of life found that vaccinated participants generally had a better quality of life, but these results were measured differently and so could not be compared. </p> <p>Five trials reported adverse effects, but there was no particular association with either the vaccine or placebo group. Further research is needed to define adverse effects as outcome measures for more definitive analyses regarding vaccine side effects. </p> <p><b>Quality of the evidence</b> </p> <p>The studies were well conducted with moderate risk of bias. The main limitation of this review was the lack of consistency regarding the definitions and outcome measures among the individual studies, which affected the overall synthesis and interpretation of the results. Fewer participants may mean the results are more likely to be affected by chance. One trial had more participants than the other five trials combined, and it contributed more to the final analysis. There was moderate heterogeneity (the studies showed quite different results) when this study was included in the analysis, especially in numbers of infections. However, the results were consistent and did not change when this study was removed from the analysis. </p> <p><b>Conclusion</b> </p> <p>We concluded after reviewing the relevant studies that the <i>H influenzae</i> vaccine taken orally in people with chronic bronchitis and COPD does not have a significant reduction in the number and severity of acute exacerbations. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010010-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010010-sec-0087"></div> <h3 class="title" id="CD010010-sec-0088">Implications for practice</h3> <section id="CD010010-sec-0088"> <p>This review analysed six trials of monobacterial whole, killed, non‐typeable <i>Haemophilus influenzae</i> (NTHi) vaccine in people experiencing recurrent acute exacerbations of chronic obstructive pulmonary disease (COPD). Our results do not support the use of the vaccine in reducing the number and severity of exacerbations. </p> </section> <h3 class="title" id="CD010010-sec-0089">Implications for research</h3> <section id="CD010010-sec-0089"> <p>Future trials should address the long‐term effects of the NTHi oral vaccine. It would be useful to further assess outcomes at both 12 months and two years following the initial vaccination, alongside gathering data on mortality, age, and other contributing factors. It may also be useful to assess the effect of regular (seasonal) vaccination over a longer period of time. Careful standardisation of the measurement protocols is necessary for consistent analyses of outcomes including number of acute infective exacerbations, severity of exacerbations, carriage levels of <i>H influenzae</i> and associated microbiology, hospital admissions, and prescription of antibiotics and corticosteroids. As polymerase chain reaction (PCR) is becoming more widely used in the diagnosis of infection, it may have a role in future research given the limitations of cultures, especially for micro‐organisms such as <i>H influenzae</i> , which are difficult to serotype. Future studies should more clearly assess and consider the use of antibiotics and steroids in COPD patients with <i>H influenzae</i>, as these are common therapies that have a significant influence on mortality and morbidity, alongside bronchodilators, oxygen therapy, and ventilatory support. </p> <p>The concept that COPD is a chronic condition with a peak incidence of diagnosis in people between 50 and 60 years of age means that patients included in studies already have well‐established airway disease. Whilst the inclusion criteria for this review and trials concerning this vaccine specified those already diagnosed with COPD, it is equally important to assess the potential benefits of vaccinating people with a predisposition to developing COPD (e.g. younger populations of heavy smokers with mild airway disease that have not yet reached a chronic condition). Future research should therefore also be directed at assessing the effects of <i>H influenzae</i> oral vaccination in high‐risk populations not yet diagnosed with COPD, as a means of establishing the prophylactic capabilities of such a vaccine. Furthermore, future studies should consider subgroup analysis between younger versus older participants to determine if there are possible benefits of earlier immunisation. </p> <p>The projected annual cost of COPD in the United States will increase from USD 176.8 to USD 832.9 billion in the next 20 years, with the majority of direct costs attributed to acute exacerbations (<a href="./references#CD010010-bbs2-0020" title="LeeTA , SullivanST , BuistAS . Estimating the future economic burden of COPD. ATS Proceedings2006;3:A598. ">Lee 2006</a>). As COPD is a non‐curable disease, any cost‐effective intervention to prevent exacerbations would be worth further research, considering the rising global prevalence and financial burden of treatment on the health system. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010010-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010010-sec-0022"></div> <div class="table" id="CD010010-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Haemophilus influenzae oral vaccination for prevention of acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><i>Haemophilus influenzae</i> oral vaccination for prevention of acute exacerbations of chronic bronchitis and COPD </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (&gt; 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis </p> <p><b>Settings:</b> community and outpatients </p> <p><b>Intervention:</b> oral monobacterial vaccination with killed NTHi </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> <p><b><i>Not vaccinated</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> <p><b><i>NTHi oral vaccinated</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute exacerbations</b> </p> <p>(number of exacerbations/person/year)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2.111 exacerbations per person/year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.668 exacerbations</b> <br/> <b>per person/year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p><b>(0.57 to 1.10)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>557<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Despite an absolute estimated decrease in the rate of exacerbations in the vaccinated group, the result is negligible (95% CI crosses 1.00) and not statistically significant (P = 0.16) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>(deaths during trial period)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (15 to 88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.62</b> </p> <p><b>(0.63 to 4.12)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Despite more absolute deaths occurring in the vaccinated group, the result is negligible (95% CI crosses 1.00) and not statistically significant (P = 0.31). Deaths were not necessarily attributed to the use of the vaccine </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carriage of NTHi</b> </p> <p><i>Not meta‐analysed</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to meta‐analyse the carriage levels of NTHi in participants as each trial reported this result using different units and tools of measurement. 4 trials showed no significant difference in carriage levels, while 2 trials showed a significant decrease in carriage levels in the vaccinated group compared with the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic prescriptions</b> </p> <p>(number of courses/person/year)</p> <p>**<i>Corticosteroids not meta‐analysed</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5.723</b> <br/> <b>prescriptions</b> <br/> <b>per person/year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3.162</b> <br/> <b>prescriptions</b> <br/> <b>per person/year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.81</b> </p> <p><b>(1.35 to 2.44)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Courses of antibiotics were found to be prescribed in the placebo group at a rate approximately 80% greater than in the vaccinated group (P &lt; 0.001) </p> <p>(Note that a RR &gt; 1.0 here indicates more antibiotics being prescribed to participants in the placebo group, i.e. RR 1.81 corresponds to an approximately 80% increased rate of antibiotic prescriptions when not receiving the vaccine. The placebo group is being compared to the vaccine group in this instance to attempt to demonstrate how many more antibiotics are required in those not vaccinated) </p> <p>**2<i>studies reported corticosteroid use, however due to differences in units of measurement, these results could not be meta‐analysed</i> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>(number of participants hospitalised during trial period)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admissions was not meta‐analysed due to differing units of measurement by the 2 trials that reported this finding. Notwithstanding that pooling the data for the 2 trials would have yielded high heterogeneity. Hospital admissions were not necessarily attributable to the vaccine </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>(number of adverse events/person/year)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.319</b> <br/> <b>adverse events</b> <br/> <b>per person/year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.456</b> <br/> <b>adverse events</b> <br/> <b>per person/year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> </p> <p><b>(0.70 to 2.92)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484<br/> (5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Despite an estimated absolute increased rate of adverse events in the vaccinated group, the result is negligible (95% CI crosses 1.00) and not statistically significant (P = 0.61). Adverse events were not necessarily attributable to the vaccine </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Not meta‐analysed</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life was not meta‐analysed due to differing units of measurement, but was reported in 2 trials, which showed an improvement at 6 months in the vaccine group (scoring at least 2 points better than the placebo group; significance unknown) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval (CI)) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>N/A:</b> not applicable; <b>NTHi:</b> non‐typeable <i>Haemophilus influenzae</i>; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>One study had marked heterogeneity; most studies had a low number of participants; one study had significant attrition.<br/> <sup>2</sup>Mortality was not formally measured; five studies reported on deaths but none attributed to vaccine.<br/> <sup>3</sup>Only three studies recorded information on prescriptions; studies had a low number of participants; method of allocation concealment and randomisation was unclear in two of the studies.<br/> <sup>4</sup>Only two studies recorded information on hospitalisations; one study was significantly larger than the other.<br/> <sup>5</sup>Most studies had a low number of participants; one study may have had attrition bias; two studies had high risk of bias for randomisation and allocation concealment.<br/> <sup>6</sup>Meta‐analysis was not performed; inconsistent units of measurement used by studies, therefore not comparable. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010010-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010010-sec-0023"></div> <section id="CD010010-sec-0024"> <h3 class="title" id="CD010010-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation that is progressive and associated with an enhanced chronic inflammatory response. The chronic airflow limitation characteristic of COPD is caused by a mixture of small airways disease (obstructive bronchiolitis) and gas‐exchange impediment through parenchymal destruction (emphysema). The changes associated with an inflammatory response include cellular infiltrate, mucus secretion, and structural remodelling, which diminish the overall ability of the airways to remain patent during expiration. This limitation in airflow, as a measurement of disease severity, is best measured and assessed by spirometry (COPD is defined as the forced expiratory volume in one second (FEV<sub>1</sub>) being lower than 80% of the predicted normal) (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>; <a href="./references#CD010010-bbs2-0026" title="OtczykD , ClancyR , CrippsA . Haemophilus influenzae and smoking‐related obstructive airways disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:345‐51. ">Otczyk 2011</a>). </p> <p>Chronic bronchitis is clinically defined by the presence of cough and sputum production for at least three months in each of two consecutive years. It is an independent disease entity that may precede or follow the development of airflow limitation and may be associated with the development or acceleration of fixed airflow limitation, or both, that is COPD. Chronic bronchitis may exist in patients with normal spirometry (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). While patients can remain undiagnosed and have no clinical evidence of a lung disease until they present with advanced COPD, many have a history of symptomatic disease, evidenced as chronic cough and sputum (chronic bronchitis) and/or recurrent episodes of acute wheezy bronchitis and/or late‐onset reversible airways disease (intrinsic asthma). Currently, the diagnosis of an acute exacerbation is based entirely on clinical presentation. There is no consensus regarding an objective measurement of an exacerbation (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). The relationship between these entities is complex and not well understood, with no obligatory linkage with COPD, but has the capacity to progress to COPD (<a href="./references#CD010010-bbs2-0026" title="OtczykD , ClancyR , CrippsA . Haemophilus influenzae and smoking‐related obstructive airways disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:345‐51. ">Otczyk 2011</a>). </p> <p>An acute exacerbation is defined as an acute event characterised by worsening of the patient's respiratory symptoms beyond normal daily variations, and can lead to a change in medication (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). The best predictors of exacerbations are a history of previously treated exacerbations and worsening airflow limitation (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). Exacerbations may be triggered by bacterial or viral infection (or both simultaneously), environmental pollutants, or as yet undetermined factors. The characteristic response is increased inflammation resulting in increased purulent sputum production, hyperinflation, and gas trapping, with reduced expiratory flow, thus accounting for the dyspnoea associated with these episodes (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). Whilst participants with an atopic constitution (hypersensitive to allergens) may be predisposed to developing COPD, it should be recognised that bacterial colonisation of damaged airways plays an important pathogenic role. In participants with established obstructive lung disease, acute attacks of infection are a major cause of morbidity and mortality. </p> <p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines estimate the prevalence of COPD to range from 7.8% to 19.7% of the population worldwide (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). Chronic obstructive pulmonary disease is very prominent in populations of smokers and ex‐smokers. However, estimates of prevalence in people who have never smoked range from 3% to 11% (<a href="./references#CD010010-bbs2-0016" title="Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention. Revised. Bethesda: National Institutes of Health, 2011. ">GOLD 2011</a>). The World Health Organization (WHO) estimates that 5% of all deaths globally can be attributed to COPD, with the disease becoming the third leading cause of death by 2030 (<a href="./references#CD010010-bbs2-0029" title="World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ 2013 (accessed 25 April 2014). ">WHO 2013</a>). Whilst epidemiological information regarding COPD comes from high‐income countries, 90% of COPD deaths occur in low‐ and middle‐income countries (<a href="./references#CD010010-bbs2-0029" title="World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ 2013 (accessed 25 April 2014). ">WHO 2013</a>). </p> <p>The management of acute exacerbations focuses on treating triggers (including infections) and relieving symptoms with bronchodilators, glucocorticoids, and antibiotics. Prevention of further exacerbations focuses on vaccination of influenza and pneumococcus strains (<a href="./references#CD010010-bbs2-0029" title="World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ 2013 (accessed 25 April 2014). ">WHO 2013</a>). A recent Cochrane review on the use of prophylactic antibiotics for COPD exacerbations concluded that there was a reduction in the number of participants experiencing exacerbations with continuous macrolide antibiotic use. The number needed to treat to prevent one exacerbation was eight. These promising findings need to be weighed against the risks from long‐term antibiotic use, such as side effects of medications and bacterial resistance (<a href="./references#CD010010-bbs2-0018" title="HerathA , PooleP . Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD009764.pub2] ">Herath 2013</a>). </p> <p>Bacterial and viral causative agents have been identified and may coexist in a benign or pathogenic capacity; because of this, the specific microbiological aetiology of acute exacerbations in chronic bronchitis and COPD patients remains a matter of debate. The pathogens responsible for these acute exacerbations are often found in the person's upper respiratory tract, and (opportunistic) infections are caused by an upset in the balance of the host‐parasite relationship. Bacterial colonisation is most common and more severe compared to viral infections. The upper respiratory tract is commonly home to <i>Staphylococcus epidermidis</i> ,<i>Staphylococcus aureus</i> ,<i>Streptococcus pneumoniae</i> ,<i>Streptococcus pyogenes</i> ,<i>H influenzae</i> , and<i>Neisseria meningitides</i> . The lower respiratory tract is normally virtually free of micro‐organisms, due to physiological clearance mechanisms (e.g. mucociliary clearance). However, should these systems become damaged (as is the case in COPD or bronchitis patients), pathogens such as non‐typeable <i>H influenzae</i> (NTHi) or <i>Pseudomonas aeruginosa</i> are usually the ones to colonise these sites (<a href="./references#CD010010-bbs2-0012" title="ButtHL , ClancyRL , CrippsAW , Murree‐AllenK , SaundersNA , SutherlandD , et al. Bacterial colonisation of the respiratory tract in chronic bronchitis. Australian and New Zealand Journal of Medicine1990;20(1):35‐8. ">Butt 1990</a>). Non‐typeable <i>H influenzae</i> is of particular importance in this scenario because of its frequent and predominant pattern of mucosal colonisation of the respiratory tract. Higher levels of immunoglobulin E (IgE) have been detected in the serum of people with COPD, and it has been observed that NTHi triggers histamine release. This process occurs through both IgE‐ and non‐IgE‐dependent mechanisms from cells contained within the respiratory mucosal sensitised to the bacterium. These findings demonstrate that NTHi may also play a role in the development of the reversible component of airways obstruction in COPD. Immediate hypersensitivity via IgE antibacterial antibodies to colonising bacteria may contribute to bronchial disease progression and severity (<a href="./references#CD010010-bbs2-0026" title="OtczykD , ClancyR , CrippsA . Haemophilus influenzae and smoking‐related obstructive airways disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:345‐51. ">Otczyk 2011</a>). As these conditions have been associated with high numbers of NTHi, the vaccine was considered to be relevant in the prevention of exacerbation frequency and severity. </p> </section> <section id="CD010010-sec-0025"> <h3 class="title" id="CD010010-sec-0025">Description of the intervention</h3> <p>Various treatment strategies have been attempted including immuno‐stimulatory agents made from bacterial extracts, such as OM‐85 BV, and antibiotics. While OM‐85 BV appears not to affect the occurrence of acute exacerbations of bronchitis, it reduces the severity of the exacerbation (55% fewer total days of hospitalisation compared to placebo) (<a href="./references#CD010010-bbs2-0014" title="ColletJP , ShapiroS , ErnstP , RenziP , DucruetT , RobinsonA , et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719‐24. ">Collet 1997</a>). Conventional antibiotic therapy has not been particularly helpful, possibly due to the inability to effectively clear respiratory flora such as NTHi, which leads to further growth and sepsis (<a href="./references#CD010010-bbs2-0015" title="FoxwellAR , KydJ , CrippsA . Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiology and Molecular Biology Reviews1998;62(2):294‐308. ">Foxwell 1998a</a>; <a href="./references#CD010010-bbs2-0024" title="MurphyT , SethiS . Bacterial infection in chronic obstructive pulmonary disease. American Review of Respiratory Disease1992;148:1067‐83. ">Murphy 1992</a>; <a href="./references#CD010010-bbs2-0028" title="VanAlphenL , JansenH , DankertJ . Virulence factors in the colonisation and persistence of bacteria in the airway. American Journal of Respiratory and Critical Care Medicine1995;151:2094‐100. ">Van Alphen 1995</a>). Recent studies have identified a role for antibiotics in the treatment of COPD (<a href="./references#CD010010-bbs2-0010" title="AlbertRK ,  ConnettJ ,  BaileyWC ,  CasaburiR ,  CooperJAJr ,  CrinerGJ ,  etal . Azithromycin for prevention of exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine2011;365:689‐98. ">Albert 2011</a>; <a href="./references#CD010010-bbs2-0023" title="MacfarlaneJ , HolmesW , GardP . Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax2001;56(2):109‐14. [DOI: 10.1136/thorax.56.2.109] ">Macfarlane 2001</a>). Although significant differences in the incidence of exacerbation were noted between groups, the long‐term effect on microbial resistance was not reported. This underscores the importance of exploring vaccination as a prophylactic treatment of COPD. </p> <p>An alternative strategy is mucosal immunisation. Successful vaccines for <i>H influenzae</i> depend on immunity stimulation against the type‐specific polysaccharide capsule of <i>Haemophilus influenzae B</i> (Hib). Following the development of successful vaccines for infections caused by Hib, attention is now focused on developing a vaccine for NTHi. Accordingly, an oral, whole‐cell NTHi vaccine has been developed to prevent NTHi infections, which is the focus of this review. </p> <p>Oral immunisation reduced bacterial loads in participants who were chronically colonised, and NTHi‐specific cellular responses were detected in white blood cells (lymphocytes) in the serum (<a href="./references#CD010010-bbs2-0025" title="OtczykDC , CrippsAW . Mucosal immunization: a realistic alternative. Human Vaccines2010;6(12):1‐29. ">Otczyk 2010</a>). This suggests that a NTHi vaccine may be useful, as it demonstrates that mucosal immunisation can be used therapeutically to enhance or modify an immune response to improve the outcomes of an established chronic mucosal infection (<a href="./references#CD010010-bbs2-0025" title="OtczykDC , CrippsAW . Mucosal immunization: a realistic alternative. Human Vaccines2010;6(12):1‐29. ">Otczyk 2010</a>). </p> </section> <section id="CD010010-sec-0026"> <h3 class="title" id="CD010010-sec-0026">How the intervention might work</h3> <p>The vaccine is believed to be most effectively absorbed through the gastrointestinal tract in order to trigger an immune response. The killed NTHi cells of the vaccine are coated with formalin to protect it from gastric degradation, thus enabling it to access the M‐cells of the gut mucosal immune system through pattern‐recognition receptors that are designed to identify pathogen‐associated molecular patterns (i.e. PRR‐PAMP interactions). Human and animal studies support the hypothesis that oral NTHi immunisation stimulates T‐cells in the Peyer's patches of the gastrointestinal tract (<a href="./references#CD010010-bbs2-0015" title="FoxwellAR , KydJ , CrippsA . Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiology and Molecular Biology Reviews1998;62(2):294‐308. ">Foxwell 1998a</a>). The T‐cells, upon stimulation from the vaccine, migrate to the respiratory system via afferent lymphatics and blood, where they are further stimulated by bacteria in the bronchial mucosa. Cytokines are secreted from the stimulated T‐cells to further increase immune activity. This results in increased recruitment and up‐regulation of neutrophil white blood cells into the bronchial space, which in turn assists in clearing bacteria through phagocytosis and thus reducing the bacterial load (<a href="./references#CD010010-bbs2-0013" title="ClancyR , DunkleyM . Acute exacerbations in COPD and their control with oral immunisation with nontypeable Haemophilus influenzae. Frontiers in Immunology2011;2:7. ">Clancy 2011</a>). </p> <p>However, it must be noted that this form of immunisation does not trigger classical mucosal immunoglobulin A responses, but rather by the means outlined above. Nonetheless, an oral vaccine of inactivated NTHi makes use of a 'physiological protective loop' to improve airway immune function. The vaccine is consumed orally and digested within the gastrointestinal tract, which triggers an innate immune response in the respiratory tract. Through a specific activation of immune cells (in the gastrointestinal tract) this initiates non‐specific protection (in the airways). Pathways that stimulate T‐helper 17 immune cells responsible for airway protection then generate an increased white blood cell responsiveness to all pathogens in the respiratory tract (<a href="./references#CD010010-bbs2-0013" title="ClancyR , DunkleyM . Acute exacerbations in COPD and their control with oral immunisation with nontypeable Haemophilus influenzae. Frontiers in Immunology2011;2:7. ">Clancy 2011</a>). </p> </section> <section id="CD010010-sec-0027"> <h3 class="title" id="CD010010-sec-0027">Why it is important to do this review</h3> <p>Chronic obstructive pulmonary disease is a major cause of morbidity and mortality. Acute exacerbations of COPD reflect intense intrabronchial inflammation, where recurrent exacerbations are linked to worsening of airflow obstruction and health status of the individual. Acute exacerbations of COPD can be fatal. Recent studies demonstrate that oral immunotherapy with NTHi reduces the level of bacterial colonisation in the airways as well as the incidence and severity of acute exacerbations (<a href="./references#CD010010-bbs2-0026" title="OtczykD , ClancyR , CrippsA . Haemophilus influenzae and smoking‐related obstructive airways disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:345‐51. ">Otczyk 2011</a>). </p> <p>As chronic antibiotic therapy is not particularly feasible, an oral, whole‐cell vaccination for NTHi has been developed to reduce morbidity and mortality in people at risk. Clinical benefit has been reflected in reduced incidence and severity of exacerbations in a number of studies. A review of trials that use oral NTHi whole‐cell vaccinations should evaluate if oral immunotherapy provides a significant therapeutic advance in limiting damage in COPD and may highlight the pathogenic role of bacterial colonisation of damaged airways. </p> <p>This is an update of a Cochrane review first published in 1998 and last updated in 2006 (<a href="./references#CD010010-bbs2-0033" title="FoxwellAR , CrippsAW , DearKBG . Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD001958.pub2] ">Foxwell 2006</a>). The previous authors concluded that participants with recurrent bronchitis vaccinated in the autumn had a decreased incidence and severity of their exacerbations during winter. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010010-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010010-sec-0028"></div> <p>To assess the effectiveness of an oral, whole‐cell NTHi vaccine in protecting against recurrent episodes of acute exacerbations of chronic bronchitis and COPD in adults. To assess the effectiveness of NTHi vaccine in reducing NTHi colonising the respiratory tract during recurrent episodes of acute exacerbations of COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010010-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010010-sec-0029"></div> <section id="CD010010-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010010-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials investigating the efficacy of an oral monobacterial NTHi vaccine in people predisposed to acute exacerbations of chronic bronchitis and COPD. </p> </section> <section id="CD010010-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults (18 years or older) with acute exacerbations of chronic bronchitis or COPD.</p> </section> <section id="CD010010-sec-0033"> <h4 class="title">Types of interventions</h4> <p>All trials comparing a monobacterial NTHi orally administered vaccine with a placebo. We included trials where bronchodilators, analgesics, and antibiotics were used in both active and placebo groups. </p> </section> <section id="CD010010-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010010-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010010-list-0001"> <li> <p>Incidence of acute exacerbations of chronic bronchitis or COPD.</p> </li> <li> <p>Mortality.</p> </li> </ol> </p> </section> <section id="CD010010-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010010-list-0002"> <li> <p>Carriage level of NTHi in the respiratory tract (including nasopharyngeal swabs, sputum samples, nasopharyngeal aspirates). </p> </li> <li> <p>Numbers of prescriptions for antibiotics and corticosteroids in the trial and follow‐up periods (including hospital admissions) as an indication of severity of acute exacerbations. </p> </li> <li> <p>Any associated adverse side effects from the NTHi vaccination, measurable from symptomology and participant reports. </p> </li> <li> <p>Quality of life. A validated tool measurement was required for trials to be included in this review. </p> </li> </ol> </p> </section> </section> </section> <section id="CD010010-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010010-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 1), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1946 to January 2017), Embase (1974 to January 2017), CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1981 to January 2017), LILACS (Latin American and Caribbean Health Sciences Literature) (1985 to January 2017), and Web of Science (1955 to January 2017). </p> <p>We used the search strategy in <a href="./appendices#CD010010-sec-0093">Appendix 1</a> to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐maximising version (2008 revision); Ovid format (<a href="./references#CD010010-bbs2-0021" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). We adapted the search strategy to search Embase (see <a href="./appendices#CD010010-sec-0095">Appendix 2</a>), CINAHL (see <a href="./appendices#CD010010-sec-0096">Appendix 3</a>), LILACS (see <a href="./appendices#CD010010-sec-0097">Appendix 4</a>), and Web of Science (see <a href="./appendices#CD010010-sec-0098">Appendix 5</a>). We used no publication or language restrictions. </p> </section> <section id="CD010010-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the clinical trials registers World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) and ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) for completed and ongoing trials (last searched January 2017). We also searched reference lists of included trials and review studies; books related to respiratory tract infections, mucosal immunology, or vaccines; abstracts from respiratory conferences, immunology conferences, microbiology conferences, or vaccine conferences; and sent written enquiries to the authors of major relevant studies and experts in the field. We also contacted pharmaceutical companies to obtain access to unpublished trials. </p> </section> </section> <section id="CD010010-sec-0040"> <h3 class="title" id="CD010010-sec-0040">Data collection and analysis</h3> <section id="CD010010-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KL, ET) assessed titles and abstracts retrieved from the search to determine their relevance to the objectives of this review. Any disagreements were resolved through discussion or by consulting a deciding arbiter (MVD). We entered all search results into Review Manager 5 (<a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD010010-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HH, SNP) designed a data extraction sheet for trial reports, which was pilot tested using sample studies and revised by the other review authors. Two review authors (HH, SNP) then independently extracted data from the reports. We extracted data from each report separately and then combined data in the event of multiple reports for the same study. Any disagreements were resolved through discussion or by consulting a deciding arbiter (MVD). </p> </section> <section id="CD010010-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KL, JP) independently analysed each trial using Cochrane's tool for assessing risk of bias (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), judging each study on the following domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential threats to validity. We rated the risk of bias for each domain as 'high', 'low', or 'unclear' and provided the supporting information that led to that rating. Any disagreements were resolved through discussion or by consulting a deciding arbiter (MVD). </p> </section> <section id="CD010010-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p> <ol id="CD010010-list-0003"> <li> <p>We presented dichotomous (binary) data as a measure of risk and relative risk by using an odds ratio (OR) or risk ratio (RR) with 95% confidence intervals (CIs). We calculated the absolute risk reduction (ARR) for consumer comparison against other treatments or non‐treatment. </p> </li> <li> <p>We presented continuous data as mean differences (MDs) if the same scale was used or as standardised mean differences (SMDs) if different scales were used with a standard deviation (SD) of the estimate. </p> </li> <li> <p>We looked for quality of life outcomes as measured in the included studies. Quality of life measurements had to be measured using a validated tool. We pooled these outcomes where possible, discussing and summarising them where this was not possible. </p> </li> <li> <p>We have pooled data reported as rates by using the inverse variance method as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </li> </ol> </p> </section> <section id="CD010010-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in our review was the participant.</p> </section> <section id="CD010010-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the trial authors of the original studies when further information was required. We performed analyses based on intention‐to‐treat (ITT), such that we assumed missing data for randomised participants to be treatment failures in this review. As this ITT analysis may underestimate the effect of the intervention, we performed both ITT and on‐treatment analyses to explore the impact of missing data on the overall outcome. We presented the findings of these analyses in the <a href="#CD010010-sec-0074">Discussion</a> section. </p> </section> <section id="CD010010-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed included trials for heterogeneity (which is a variation in study outcomes amongst the studies as further defined in <a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) through two successive steps to determine if they should be pooled with the rest of the included trials or reported in a systematic review. </p> <p> <ol id="CD010010-list-0004"> <li> <p>Two review authors (KL, JP) independently analysed trials for their 'face‐value' similarities, i.e. for clinical diversity (participants, interventions, and outcomes) and methodological diversity (study design and risk of bias). </p> </li> <li> <p>We subsequently assessed trials for statistical heterogeneity using the Chi<sup>2</sup> test with a P value of less than 0.10 being statistically significant. We calculated the I<sup>2</sup> statistic as instructed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). If this was greater than 50%, we considered the pooled trials to be significantly heterogeneous. </p> </li> </ol> </p> </section> <section id="CD010010-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>Had a sufficient number of studies had been pooled (i.e. greater than 25), we planned to use a funnel plot to visually inspect the risk of publication bias, where more pronounced asymmetry of the funnel plot may be indicative of a substantial overestimation of the intervention effect (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD010010-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We synthesised the data as follows.</p> <p> <ol id="CD010010-list-0005"> <li> <p>We used a fixed‐effect model for binary or continuous data in the absence of statistical heterogeneity (I<sup>2</sup> &lt; 50%) according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </li> <li> <p>We used a random‐effects model for binary or continuous data in the presence of statistical heterogeneity (I<sup>2</sup> &gt; 50%) for pooling the trial data using the Mantel‐Haenszel method according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). This model of analysis makes the assumption that the studies are not measuring for the same intervention effect, instead estimating for an overall intervention effect that is trending amongst the studies. </p> </li> <li> <p>We also used the fixed‐effect model to pool study data that reported events as rates according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; only fixed‐effect meta‐analysis methods are available in Review Manager 5 for 'O – E and Variance' outcome (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD010010-bbs2-0027" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </li> </ol> </p> <section id="CD010010-sec-0050"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following outcomes: acute exacerbations, mortality, carriage levels, antibiotic prescriptions, hospital admissions, adverse events, and quality of life<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD010010-bbs2-0011" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010010-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), using GRADEpro GDT software (<a href="./references#CD010010-bbs2-0017" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 2014. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). We justified all decisions to down‐ or upgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary. </p> <p>Outcomes that presented data as dichotomously, had their assumed risk calculated by taking the proportion of participants in the placebo group that encountered the event, and thus, the corresponding risk calculated by applying the relative effect to the assumed risk. </p> <p>Outcomes that presented data as rates, had their assumed risk calculated by taking the average rate of events in the placebo group (measured in events per person per year), and thus, the corresponding risk calculated by applying the relative effect to the assumed risk. Refer to the Additional tables for the event rates for each of the studies included in the meta‐analysis. </p> </section> </section> <section id="CD010010-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient data were available, we planned to explore specific subgroups for further analyses of treatment effect. </p> <p> <ol id="CD010010-list-0006"> <li> <p>Comparison of continued‐smoking versus ex‐smoking populations.</p> </li> <li> <p>Younger (&lt; 65 years) versus older (65 years and older) participants.</p> </li> </ol> </p> </section> <section id="CD010010-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>If sufficient data were available, we planned to perform sensitivity analyses by:</p> <p> <ol id="CD010010-list-0007"> <li> <p>examining how the addition of studies at high risk of bias to studies at low risk of bias impacted on the overall outcome to determine the effects of risk of bias; and </p> </li> <li> <p>examining which studies contributed to heterogeneity and how this impacted on the overall outcome. </p> </li> </ol> </p> <p>We used different methods of pooling, for example initially pooling all trials and then excluding one by one specific trials from the meta‐analysis and comparing the results, whilst also comparing the use of a fixed‐effect versus random‐effects model for the pooling analysis. Otherwise, we entered trials one by one into the meta‐analysis to assess the robustness of the pooled estimates. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010010-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010010-sec-0053"></div> <section id="CD010010-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD010010-sec-0055"> <h4 class="title">Results of the search</h4> <p>We obtained 199 records from our searches as described in <a href="#CD010010-sec-0037">Search methods for identification of studies</a>. From the search result, we identified 10 randomised controlled trials (RCTs) that provided data pertinent to the NTHi oral vaccine in preventing acute exacerbations in chronic bronchitis and COPD (<a href="#CD010010-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010010-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Inclusion of trials flow diagram." data-id="CD010010-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Inclusion of trials flow diagram.</p> </div> </div> </div> </section> <section id="CD010010-sec-0056"> <h4 class="title">Included studies</h4> <p>We included six studies in this review (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). We have summarised the main features of the included trials in the <a href="./references#CD010010-sec-0107" title="">Characteristics of included studies</a> table. We have summarised the key results of the included trials in the <a href="./full#CD010010-tbl-0001">summary of findings Table for the main comparison</a>. We have described the methods here in greater detail, largely using direct excerpts of the original papers, as these demonstrate the strengths and weaknesses of the trials in the words of the original authors. </p> <section id="CD010010-sec-0057"> <h5 class="title">Overview</h5> <p>All six of the included studies were clinical placebo‐controlled RCTs, five of which were double‐blinded (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>), and one of which was single‐blinded (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>). They were conducted to test the efficacy of enteric‐coated, killed preparations of <i>H influenzae</i> in populations prone to recurrent acute exacerbations of chronic bronchitis or COPD. The vaccine preparation and immunisation regimen used in all trials consisted of at least three courses of formalin‐killed <i>H influenzae</i> in enteric‐coated tablets taken at intervals (e.g. on days 0, 28, and 56). Each course generally consisted of two tablets taken after breakfast over three consecutive days. In all cases, the placebo groups took enteric‐coated tablets containing glucose. </p> <p>The trials varied in duration from three to 12 months. Randomisation in the trials was achieved by having a pharmacist independently prepare treatment packages that contained either active or placebo tablets (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>). These packages were numbered and randomised before being distributed to the clinicians involved in the trials, where the pharmacist was responsible for disclosing the randomised codes at the conclusion of the trial. </p> <p>The trials varied in population groups, with most trials including chronic bronchitis or COPD patients in Australia with mean ages between 40 and 80 years (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> was conducted in chronic bronchitis or COPD patients in Papua New Guinea, with a mean age of 51 years. </p> <p>Bacterial load was assessed by a standardised method across the six trials. Multiple cultures were performed on each person. In normal circumstances, the first culture following vaccination was taken at three months. Cultures were taken at regular three‐monthly intervals and extra cultures taken during illness. The methods of obtaining samples and transporting material and culture methods generally followed a set protocol for adequate specimen handling and control. However, the lack of consistency and wide variety of measurement styles used amongst the studies to calculate and report carriage levels made analyses between studies difficult. </p> <p>Measured outcomes in the trials varied but included bacterial load within the respiratory tract, the number and severity of acute exacerbations, and the usage of antibiotics. These outcomes were not always statistically useful. </p> <p>Corticosteroids were administered at a similar rate in both active and placebo groups. Antibiotics were prescribed in both arms of the trial according to standard respiratory medicine clinical criteria at the time of the respective trials. Such criteria included increase in volume and purulence of sputum, usually with increased breathlessness and sometimes fever. </p> <p><a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> was carried out and published by Clancy in 1985 and 1987 and is the oldest trial relevant to this review. It is a double‐blind, placebo‐controlled RCT conducted in New South Wales (Australia) over a period of three months in the winter of 1983. The mean age was 65.5 years in the treatment group and 64.7 years in the placebo group. The focus of the study was the immunogenicity of the <i>H influenzae</i> oral vaccine and the clinical impact on people with airways damaged by COPD who suffered recurrent episodes of acute bronchitis. Fifty people with COPD (not taking corticosteroids or immunosuppressants) were recruited from the chest clinic of the Royal Newcastle Hospital and were given a three‐day course of tablets (two daily) at 0, 28, and 56 days. Both placebo and NTHi vaccine were enteric‐coated. <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> utilised two placebo arms in their trial: the first group was given enteric‐coated glucose tablets, and the second was given sodium tauroglycocholate. We have used the results from the first placebo group as this is a standard, widely used placebo, rather than the sodium tauroglycocholate group, as this placebo may have contributed some therapeutic effect. Participants were assessed by a chest physician, with lung function (spirometry), throat cultures, and saliva samples collected at baseline, 28, 56, and 84 days. The characteristics of participants entered into the trial demonstrated a very representative population: older adults (mean age 65 years), majority male (M:F 4.5:1), majority smokers (86%). <i>H influenzae</i> was isolated from 69% of sputum samples collected during acute bronchitis episodes in this population. <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> concluded that the NTHi vaccine resulted in over 90% protection against acute exacerbations compared to the placebo group. This was not the case at follow‐up a year later, at which point there was no significant reduction in incidence of <i>H influenzae</i> carriage, that is no clear correlation between clinical protection from acute exacerbations and either carriage of <i>H influenzae</i> or the level of antibody to <i>H influenzae</i> antigen in saliva was evident. It was also noted that the protection provided by the vaccine did not extend to the subsequent winter, which is consistent with the knowledge that mucosal immunity is less durable than systemic immunity. </p> <p><a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a> was a double‐blind RCT conducted in Australia over a six‐month period. There were a total of 37 participants with each group having similar baseline characteristics. The population in this study had a mean age of 65.5 +/‐ 2.9 and was recruited from a chest clinic in Newcastle. Episodes were defined by an increase in purulence and volume of sputum with associated fever, cough, shortness of breath, and antibiotic therapy. Each participant was assessed by a chest physician, completed a respiratory questionnaire (American Thoracic Society Division of Lung Disease questionnaire (ATS‐DLD‐78)), and had sputum and mixed saliva samples taken and lung function via spirometry. Each group received three courses of oral tablets for three consecutive days at 0, 28, and 56 days. One group received the active preparation containing <i>H influenzae</i> vaccine, while the other group received a glucose‐containing placebo preparation. There was a significant reduction in the number of episodes of acute wheezy bronchitis in the treated group with a P value of 0.02. There was a significant reduction (41%) in the total number of acute infections in the treatment group compared to the placebo group but no significant change when acute infections were considered in an individual from either group. This study had other modes of measuring severity, such as the number of participants reporting infections and the number of infections prescribed antibiotics, and all results supported the treatment group. There was no significant difference noted in the side effect profile in either group. </p> <p><a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> was a double‐blind, placebo‐controlled, prospective study conducted for nine months over the Australian winter of 2011. The study included 320 people with moderate‐severe COPD with FEV<sub>1</sub> less than 60%, requiring oral systemic corticosteroid therapy or admission into hospital, recruited from 21 sites across Australia; the mean age of participants was 71.2 years in the treatment arm and 67.9 years in the placebo arm. Participants in the intervention group were given two HI‐164 oral vaccine enteric‐coated tablets per day, each of which contained 45 mg of the formalin‐inactivated NTHi (HI‐164) active vaccine; participants in the placebo group received a glucose substitute. Study outcomes assessed the number of exacerbations (according to the St George's Respiratory Questionnaire for COPD), carriage levels (from cultured sputum samples), hospitalisations, and antibiotic/steroid prescriptions (based on medical records). The aim of this study was to extend the database from earlier and smaller studies showing that maximum protection occurred in those with most severe disease, with the most sensitive indicator being a reduction in exacerbations requiring corticosteroid therapy or hospital admission, or both. <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> provides evidence that the age‐related vaccine benefits in COPD noted with parenteral vaccines also apply to oral vaccines that enhance mucosal immunity within the bronchus. The results were only minutely significant in circumstances of low exposure to NTHi and only amongst a subgroup of younger participants (aged under 65), given more responsive immune systems and less established airway disease. The results were otherwise not significant for those older than 65 years of age. </p> <p><a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> was a prospective, double‐blind RCT, conducted through the Pneumonia Research Programme in Papua New Guinea. As a result, the demographic characteristics differed significantly to those found in high‐income communities. Potential participants were identified by nomination from town residents and villagers and were then followed up by a standard questionnaire, which identified people suffering from chronic lung disease. Participants who matched the eligibility criteria were examined with lung function tests and spirometry at time of entry into the trial. Randomisation and blinding of medication and placebo were done by the pharmacy department at the Royal Newcastle Hospital, New South Wales, Australia; the placebo and active vaccine looked identical, and the randomisation code was held by Auspharm International Ltd until the completion of the trial. Both groups were similar at baseline following allocation. Doctors and nurses oversaw the administration of medication to maintain compliance during the 12‐month follow‐up period. Eight participants in the vaccine group and three in the placebo group were lost to follow‐up, with three deaths in the vaccine group and one death in the placebo group. The trial does not mention any ITT analysis for these participants, rather stating "permanent exit from the study were excluded from the calculation", potentially creating attrition bias. The trial concludes that for the population of the highlands of Papua New Guinea, the vaccine protected against episodes of acute bronchitis, but not against more severe forms of acute lower respiratory tract infection. A limitation of the study was the need for a larger population group to ensure greater statistical power to help determine the extent of protection oral <i>H influenzae</i> vaccine could provide. </p> <p><a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> was a double‐blind RCT, conducted in 1988 at the repatriation hospital in Western Australia. This study recruited 64 participants with chronic bronchitis and a history of recurrent respiratory tract infections to learn whether oral NTHi immunisation is effective in this patient population. Participants were divided randomly into placebo (mean age 71.1 years) and vaccine (mean age 73.1 years) groups. All participants followed the same treatment regimen consisting of three courses of the tablets on days 0, 28, and 56. Study outcomes were acute infective episodes, number of antibiotic prescriptions, and colonisation with <i>H influenzae</i> , monitored through the following strategies: primary care physician for diagnosing acute infective episodes, sputum sample, and visual analogue scale. For all of these variables, better outcomes were demonstrated in the vaccine group. Previous studies have demonstrated that <i>H influenzae</i> is the main constituent in bacterial colonisation of the bronchus, and therefore vaccinating against it would reduce the incidence of acute exacerbations, which is consistent with the results of this study. </p> <p><a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> was a multicentre, double‐blind, placebo‐controlled trial conducted at four sites around Australia. The study tested the efficacy of HI‐164OV in reducing the number and severity of acute exacerbations in people with severe COPD. Acute exacerbations were defined by an increase in volume and purulence of sputum. Each participant was administered the same regimen (two tablets daily for three consecutive days) with courses repeated at day 28 and 56. All tablets were identical‐looking, enteric‐coated capsules that contained either vaccine (N = 18) or placebo (N = 20). Participants were followed up every four weeks via a respiratory questionnaire, sputum and nasopharyngeal swabs were collected to monitor bacterial colonisation, and blood samples were collected to monitor antibodies. The primary variables were the number and duration of exacerbations and the number of antibiotic courses prescribed. Baseline demographic characteristics, such as mean age (vaccine 69.5, placebo 67.5) were very similar, demonstrating effective randomisation. However, the exact method of randomisation was not disclosed. Four of the six authors of this study disclosed that they had received funding from Hunter Immunology Ltd. The authors concluded that the vaccine was safe and had a significant efficacy in participants with severe COPD. Benefits were noted with respect to a reduction in the severity of episodes (duration of episodes; 14.3 vaccine group and 22.7 placebo, P &lt; 0.01), which required less antibiotic therapy (event rate; 0.83 vaccine and 1.15 placebo, P &lt; 0.05) and fewer admissions to hospital (three in the vaccine group compared to 12 in the placebo group, P &lt; 0.05). However, a reduction in the incidence of episodes did not reach significance, possibly because the study was significantly underpowered. </p> </section> </section> <section id="CD010010-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded one study because it did not meet our inclusion criteria (<a href="./references#CD010010-bbs2-0007" title="ClancyRL , DunkleyML . Oral non‐typeable Haemophilus influenzae enhances physiological mechanism of airways protection. Clinical &amp; Experimental Immunology2010;161(1):127‐33. ">Clancy 2010</a>). As noted in <a href="./references#CD010010-sec-0108" title="">Characteristics of excluded studies</a>, the participant population included smokers who did not have formally diagnosed COPD or chronic bronchitis, and outcome measures were limited to physiological markers that did not include the clinical outcomes defined in this review's protocol. </p> <p>Two studies are cited only in trial registries and are pending formal publication of the raw trial data by the investigators (<a href="./references#CD010010-bbs2-0008" title="ACTRN12606000074594 . A multi‐centre, double blind, placebo controlled, prospective study to assess safety and efficacy of orally administered killed whole cell nontypeable Haemophilus influenzae (NTHi) HI‐1‐164 in preventing episodes of acute bronchitis in patients with moderate to severe airway disease. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=126060000745942013. ">ACTRN12606000074594</a>; <a href="./references#CD010010-bbs2-0009" title="ACTRN12606000076572 . A multi‐centre, double blind, placebo controlled, prospective study to assess safety and efficacy of orally administered killed whole cell nontypeable Haemophilus influenzae (NTHi) HI‐1‐164 in preventing episodes of acute bronchitis in patients with mild to moderate airway disease. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=11212013. ">ACTRN12606000076572</a>). The main features of these unpublished trials can be found in <a href="./references#CD010010-sec-0109" title="">Characteristics of studies awaiting classification</a>. These trials will potentially be incorporated into future updates of this review. </p> </section> </section> <section id="CD010010-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the 'Risk of bias' assessment is detailed in the <a href="./references#CD010010-sec-0107" title="">Characteristics of included studies</a> table. </p> <section id="CD010010-sec-0060"> <h4 class="title">Allocation</h4> <p>The random sequence generation in the studies was generally determined to be poor, with 50% of the studies graded as either at high or unclear risk of bias because they did not provide any information regarding the random sequence generation and subsequent allocation process (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). We considered the remaining studies to have a low risk of bias given that it was reported that a third party conducted randomisation and that the allocation codes were kept confidential until the end of the trial (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>). </p> <p>The allocation concealment in the selected studies was generally poor, with 67% of the studies categorised as either at unclear or high risk of bias (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). Only two studies demonstrated a low risk of bias, where the handling and distribution of the treatment packages were carried out independently by the pharmacist, who employed an appropriate randomisation chart and safely kept the package trial code associated with the participants (<a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>). </p> </section> <section id="CD010010-sec-0061"> <h4 class="title">Blinding</h4> <p>All studies performed suitable blinding except for one, which we deemed to be at high risk of bias because it did not blind the commercially available polybacterial tablets (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>); for this reason, the study was subsequently conducted as a single‐blind trial (participants blinded). All of the remaining studies reported using double‐blinded identical enteric‐coated tablets for both intervention and placebo arms of the trial. </p> </section> <section id="CD010010-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Five of the six included studies accounted for and provided sufficient information regarding the follow‐up of participants who had dropped out of the trials (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> made no mention of ITT analysis and reported a substantial loss to follow‐up (eight participants from the vaccine group and three from the placebo group), especially considering the small group size. </p> </section> <section id="CD010010-sec-0063"> <h4 class="title">Selective reporting</h4> <p>We found no selective reporting in any of the studies.</p> </section> <section id="CD010010-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias in any of the studies.</p> </section> </section> <section id="CD010010-sec-0065"> <h3 class="title" id="CD010010-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD010010-tbl-0001"><b>Summary of findings for the main comparison</b><i>Haemophilus influenzae</i> oral vaccination for prevention of acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD)</a> </p> <section id="CD010010-sec-0066"> <h4 class="title">Primary outcomes</h4> <section id="CD010010-sec-0067"> <h5 class="title">1. Incidence of acute exacerbations of chronic bronchitis or chronic obstructive pulmonary disease (COPD) </h5> <p>Six trials evaluating 557 participants assessed the effectiveness of non‐typeable <i>Haemophilus influenzae</i> (NTHi) oral vaccination on the frequency of acute exacerbations in people with advanced lung disease (<a href="#CD010010-fig-0002">Figure 2</a>; <a href="#CD010010-tbl-0002">Table 1</a>). The meta‐analysis concluded that there was a small, non‐significant 2.048% decrease in exacerbations in the vaccinated group when compared to the placebo group (RR 0.79, 95% CI 0.57 to 1.10; P = 0.16) (<a href="./references#CD010010-fig-0006" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD010010-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Primary outcomes, outcome: 1.1 Exacerbations (number of exacerbations/person/year).Refer to for Overall rate estimates of acute exacerbations across included studies." data-id="CD010010-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Primary outcomes, outcome: 1.1 Exacerbations (number of exacerbations/person/year). </p> <p>Refer to <a href="#CD010010-tbl-0002">Table 1</a> for <i>Overall rate estimates of acute exacerbations across included studies</i>. </p> </div> </div> </div> <div class="table" id="CD010010-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Rate estimates of acute exacerbations across included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Vaccinated</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> *Absolute rate difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 1985</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.256</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.272</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.016 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 1990</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.700 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.717</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.767</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.050 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lehmann 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.800</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.410 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.355</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.009 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.667</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.350</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.683 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall mean</b> </i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1.633</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2.111</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.478 (‐)</i> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Estimated rate of exacerbation calculated as number of exacerbations per person per year. </p> <p>Refer to <a href="./references#CD010010-fig-0006" title="">Analysis 1.1</a>: <i>Forest plot comparison and rate ratios for exacerbations</i>. </p> </div> </div> <p>Despite all trials having almost identical primary objectives, there were considerable discrepancies in the manner in which the primary outcomes were reported. For example, <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> reported overall number of infections, whereas <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> reported the number of infections per participant. In order to allow meaningful comparisons between studies, we converted all data into a rate of exacerbations (number of exacerbations per participant per year). </p> <p>Of the six studies incorporated into the review, only one demonstrated an effect that favoured the vaccination group (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>). <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> was a small trial that enrolled 33 participants. The data showed a very significant positive effect in favour of the vaccine group, recording only one event compared to 13 in the placebo group, which was statistically significant (RR 0.07, 95% CI 0.01 to 0.55), despite the very large CI. However, subgroup analysis demonstrated that removing this study from the pool had no bearing on the overall meta‐analysis outcome, as its small population meant this study's weighting was very small. </p> <p>Five studies, with a total of 504 participants, did not show a significant increase in the number of exacerbations (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). As a result, their combined contribution to this meta‐analysis weighting was 99.5%. </p> <p><a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> was the largest trial, comprising 320 participants and receiving over 70% of the meta‐analysis weighting. It showed a non‐significant 8% increase in the number of exacerbations in the placebo group (RR 1.08, 95% CI 0.91 to 1.29). <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> reported 249 events in the vaccine group compared with 270 in the placebo group. </p> <p>There was a moderate degree of heterogeneity in this meta‐analysis (I<sup>2</sup> = 57%, P = 0.04), hence a random‐effects model of analysis was used. The study contributing most to this effect was <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>. Removal of <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> dramatically reduces the heterogeneity (I<sup>2</sup> = 24%, P = 0.26), but did not change the overall result. </p> </section> <section id="CD010010-sec-0068"> <h5 class="title">2. Mortality</h5> <p>None of the trials formally assessed mortality as an outcome. However, five trials reported death of trial participants (<a href="#CD010010-fig-0003">Figure 3</a>) (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991;</a><a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). Of these deaths, none were attributed to the vaccine and most were considered the natural endpoint of the participants' respiratory disease or other unrelated chronic disease. There was a greater incidence of mortality in the placebo group. However, this result was not statistically significant (OR 1.62, 95% CI 0.63 to 4.12; P = 0.31), with a low amount of heterogeneity between results (I<sup>2</sup> = 9%, P = 0.36) (<a href="./references#CD010010-fig-0007" title="">Analysis 1.2</a>). </p> <div class="figure" id="CD010010-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Primary outcomes, outcome: 1.2 Mortality (deaths during trial period)." data-id="CD010010-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Primary outcomes, outcome: 1.2 Mortality (deaths during trial period). </p> </div> </div> </div> </section> </section> <section id="CD010010-sec-0069"> <h4 class="title">Secondary outcomes</h4> <section id="CD010010-sec-0070"> <h5 class="title">1. Carriage level of NTHi in the respiratory tract</h5> <p>All six RCTs attempted analysis of carriage levels of <i>H influenzae</i> in participants. We could not perform a meta‐analysis as a myriad of different techniques were used to measure carriage levels objectively (throat swabs, sputum samples and culture), and carriage rates were measured at different intervals. Three trials failed to find a significant difference between carriage levels (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>). Two studies showed a significant decrease in carriage rates in the vaccine group (<a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). In one study, carriage levels were measured, but sputum samples could only be obtained at 36% of planned visits, of which 11% grew a respiratory pathogen; these numbers were too small to determine any significant effect following vaccination (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>). </p> <p><a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> showed the mean concentrations of <i>H influenzae</i> carriage levels during acute exacerbations to be higher in the vaccine group (8.91 x 10<sup>6</sup> colony‐forming units (cfu)) when compared against the placebo (1.55 x 10<sup>6</sup> cfu). However, this only equated to a 5% difference between the vaccinated and placebo arms when counting individual specimens, whereby 91% of the vaccinated and 86% of the placebo collected specimens successfully grew <i>H influenzae</i> colonisations during the trial period. </p> <p><a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> demonstrated that there was a significant (P &lt; 0.05) two‐fold difference between the placebo and active arms in overall positive cultures (65 positive cultures in the placebo group compared to 33 in the vaccine group). However, the percentage of validated sputum samples was 50% and 48% for placebo and active groups, respectively. <i>H influenzae</i> accounted for only 51% and 33% of positive cultures in the placebo and vaccinated groups, respectively. </p> <p>There was a trend for studies to report a transient decline in <i>H influenzae</i> carriage levels. However, this had always returned to baseline by the end of the study time frame. <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> noted a transient drop in carriage levels to 12% at 14 weeks in the active group, which then reverted back to 25% at 24 weeks. This is a 4% drop over 24 weeks. The placebo group noted a small 2% drop over the 24‐week study period. Furthermore, in <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a><i>H influenzae</i> was isolated from throat swabs from 70% of the placebo group compared with 53% of the vaccination group at the end of a four‐week period. Carriage rates at 12 weeks declined to 50% in the placebo group and 23% in the vaccine group. </p> </section> <section id="CD010010-sec-0071"> <h5 class="title">2. Numbers of prescriptions for antibiotics and corticosteroids in the trial and follow‐up periods (including hospital admissions) as an indication of severity of acute exacerbations </h5> <p>Four studies, evaluating 462 participants, assessed the effect of NTHi oral vaccination on the number of antibiotic prescriptions in people with chronic bronchitis (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>) (<a href="#CD010010-fig-0004">Figure 4</a>; <a href="#CD010010-tbl-0003">Table 2</a>). </p> <div class="figure" id="CD010010-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Prescriptions (number of courses/person/year).Refer to for Overall rate estimates of antibiotic prescriptions across included studies." data-id="CD010010-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Prescriptions (number of courses/person/year). </p> <p>Refer to <a href="#CD010010-tbl-0003">Table 2</a> for <i>Overall rate estimates of antibiotic prescriptions across included studies</i>. </p> </div> </div> </div> <div class="table" id="CD010010-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rate estimates of antibiotic prescriptions across included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Vaccinated</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> *Absolute rate difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 1990</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.700 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.806</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.388 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.180</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.020 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall mean</b> </i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>3.162</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>6.198</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>3.036 (‐)</i> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Estimated rate of antibiotic prescriptions calculated as number of antibiotic courses per person per year. </p> <p>Refer to <a href="./references#CD010010-fig-0008" title="">Analysis 2.1</a>: <i>Forest plot comparison and rate ratios for antibiotic prescriptions</i>. </p> </div> </div> <p>There were considerable discrepancies amongst studies in the way antibiotic prescriptions were objectively measured. We attempted to convert the reported data into a rate (number of courses/person/year) in order to achieve an objective comparison. However, this was not possible with data from the <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> trial, which unlike the other studies only reported mean antibiotic use in days. As a result, we could pool only three studies in meta‐analysis. Two studies did not report any information on antibiotic usage in this population (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>). </p> <p>The three studies in the meta‐analysis included 143 participants (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). Two of these studies produced data that favoured the vaccination group (<a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>), whereas the <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a> data did not reach significance. The overall effect was a statistically non‐significant 81% increase in use of antibiotic courses per person in the placebo group when compared against the vaccinated group (RR 1.81, 95% CI 1.35 to 2.44; P &lt; 0.001; with a RR &gt; 1.0 indicating greater antibiotic usage in the placebo group) (<a href="./references#CD010010-fig-0008" title="">Analysis 2.1</a>). The majority of the weighting could be attributed to <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> and <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>: 64.9% and 31.1%, respectively, and both favoured the vaccination group. </p> <p><a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> showed a significant decrease in antibiotic prescriptions (45 in the active group and 79 in the placebo group). <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> showed a significant 56% reduction in the number of prescribed antibiotics following active treatment (P &lt; 0.05). <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a> reported a reduction in the number of antibiotics in the active group compared to the placebo group, but this failed to reach statistical significance. </p> <p>The <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> trial is by far the largest study in this review (three times the combined size of the other three trials included in this outcome), contributing 320 of the 462 participants. Clancy reported that there was no significant difference between the two groups in terms of antibiotic usage (active group 13.5 days per episode with a range of 0 to 289; placebo group 14 days per episode with a range of 1 to 122). Given the wide and varied protocols for antibiotic administration, it was impossible to translate this into course/person/year as with the other trials. </p> <p>Corticosteroid prescriptions were not strictly studied as an outcome in the studies, and thus we did not meta‐analyse these; nonetheless, usage was noted in participants in at least two studies (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>), and we have considered their indications and study findings for their use in the <a href="#CD010010-sec-0075">Summary of main results</a>. </p> <p>Hospitalisation data amongst the studies were limited, with only two studies reporting hospitalisations of their participants (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). The two studies presented data different units of measurement therefore not allowing the 2 studies to be meta‐analysed together; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> presented their data has a rate ratio, whereas <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> presented data dichotomously. We have considered their indications and study findings for their use in the <a href="#CD010010-sec-0075">Summary of main results</a>. </p> </section> <section id="CD010010-sec-0072"> <h5 class="title">3. Any associated adverse side effects from the NTHi vaccination, measurable from symptomology and participant reports </h5> <p>All studies except <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> reported adverse events, although none of the trials studied this as an outcome. In total, 142 adverse events were reported; of these, 72 occurred in the active group and 68 occurred in the placebo group (<a href="./references#CD010010-fig-0009" title="">Analysis 2.2</a>; <a href="#CD010010-fig-0005">Figure 5</a>; <a href="#CD010010-tbl-0004">Table 3</a>). Reported adverse effects were largely gastrointestinal in nature, although increased dyspnoea or general malaise were also commonly reported; none of these were found to be directly attributable to the oral vaccine. </p> <div class="figure" id="CD010010-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Adverse events (number of adverse events/person/year).Refer to for Overall rate estimates of adverse events across included studies." data-id="CD010010-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Adverse events (number of adverse events/person/year). </p> <p>Refer to <a href="#CD010010-tbl-0004">Table 3</a> for <i>Overall rate estimates of adverse events across included studies</i>. </p> </div> </div> </div> <div class="table" id="CD010010-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Rate estimates of adverse events across included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Vaccinated</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> *Absolute rate difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.025</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.017 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lehmann 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.067</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.031</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.036 (+)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.032</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.212</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.180 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.450</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.283 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall mean</b> </i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.319</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.430</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.111 (‐)</i> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Estimated rate of adverse events calculated as number of adverse events per person per year. </p> <p>Refer to <a href="./references#CD010010-fig-0009" title="">Analysis 2.2</a>: <i>Forest plot comparison and rate ratios for adverse events</i>. </p> </div> </div> <p><a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> reported that adverse event rates were similar in both groups (33.5% in the placebo group compared with 38.5% in the vaccinated group), although the actual number of events was not provided in the original publication. Further data provided by the study authors showed that one participant in the active group had an adverse event compared with three participants in the placebo group. </p> </section> <section id="CD010010-sec-0073"> <h5 class="title">4. Quality of life</h5> <p>Two studies reported quality of life measurements, however as they used different assessment scales they were not comparable and we therefore did not meta‐analyse them (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>). <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> reported a global assessment for general well‐being using a visual analogue scale, which showed at 24 weeks a median score of 5.0 in the vaccine group compared to 2.5 in the placebo group (P = 0.09). <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> measured quality of life using the St George's Respiratory Questionnaire for COPD for those under 65 years old, reporting a significant difference in symptom scores in favour of the vaccine group at three months (P = 0.02) and six months (P = 0.01). Data were not provided for older age groups. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010010-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010010-sec-0074"></div> <section id="CD010010-sec-0075"> <h3 class="title" id="CD010010-sec-0075">Summary of main results</h3> <section id="CD010010-sec-0076"> <h4 class="title">Incidence of acute exacerbations of chronic bronchitis or COPD</h4> <p>In this review we evaluated the effectiveness of a NTHi oral vaccination in reducing acute exacerbations in people with chronic bronchitis/COPD. The results indicated that the vaccination has no significant impact in reducing the number of exacerbations. Only one study was able to demonstrate a statistically significant effect, which favoured vaccination (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>). This was the smallest study and contributed significant heterogeneity to the meta‐analysis. When we removed <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> from the meta‐analysis, we found no significant difference for the primary outcome. All other studies showed no significant treatment effect. </p> <p>Among the studies included in the review, there were considerable differences in the methodology and intervals at which measurements were recorded. The main outcome (acute exacerbations) was measured differently across the six studies, providing a challenge for comparison. For example, <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> records results as a proportion, whereas <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> utilises rates. There were also notable discrepancies in the study time periods, with <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> reporting data at three months and <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a> providing data up to six months. Data recorded at nine to 12 months could only be elicited from two trials. As a result, we converted all data into rates so that studies could be objectively compared, irrespective of their varying follow‐up protocols. </p> <p>Other differences amongst the trials included variation in population (<a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> was conducted in Papua New Guinea), the use of subjective measurements such as respiratory questionnaires to measure exacerbations, and seasonal variations. These may have contributed to the marked heterogeneity (I<sup>2</sup> = 57%, P = 0.04) identified in the meta‐analysis. </p> <p>Only one study was large enough to be able to conduct subgroup analysis stratified by age (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>). A subgroup analysis excluding all participants older than 65 years concluded that the mean number of exacerbations was significantly higher in the placebo group (56) when compared to the vaccinated group (34) (P &lt; 0.001). There was also a statistically significant difference in the days to first exacerbation (87 days in the placebo group compared to 111 days in the vaccine group). Although the data at this stage were limited, these results suggest the use of the NTHi vaccination in a younger population, especially considering that there was no difference in mortality or adverse events in the two groups. The apparently greater efficacy of the vaccine seen in those less than 65 years old may be a reflection of a less severe burden of disease; younger patients generally have a shorter smoking history, fewer exacerbations, and fewer comorbidities. Further studies need to be conducted in younger patients and considering the varying severity of COPD to identify whether there is a significant treatment effect in this population. </p> </section> <section id="CD010010-sec-0077"> <h4 class="title">Mortality</h4> <p>We found mortality rates overall to be higher in the placebo group. However, these results were not statistically significant and are unconvincing. There was no apparent association with treatment effect, and it is unclear whether the administration of the NTHi vaccine contributed to mortality. </p> <p>Other patient factors were suggested to contribute to mortality in some trials, such as long‐standing cirrhosis or a ruptured aneurysm reported in <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> and <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>. These comorbidities would have a significant effect on the mortality outcome given the small participant numbers. </p> <p>Two trials reported the primary cause of death as a terminal respiratory infection (<a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>), with other studies reporting cause of death to be non‐respiratory. Whilst it is understood that the most common cause of death in COPD patients is respiratory failure, it was not clearly demonstrated in this meta‐analysis, which was likely due to inconsistent and insufficient reporting in the studies. </p> </section> <section id="CD010010-sec-0078"> <h4 class="title">Carriage level of NTHi in the respiratory tract</h4> <p>All six trials measured sputum carriage levels of <i>H influenzae</i>; these were obtained routinely and during acute exacerbations, although the methods of reporting and intervals at which routine samples were taken varied. This limited the extent to which these results could be compared. </p> <p>A significant difference in the carriage rates was not consistently found between the placebo and vaccine groups in every trial. No significant difference over time in routine carriage rates was found between the groups in <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>, <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>, and <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>. The largest of the studies obtained samples at only 36% of visits, and of these, a respiratory pathogen was isolated in only 11% (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>). The sputum carriage levels were too small to determine any significant effect following vaccination. </p> <p>In the majority of trials, <i>H influenzae</i> was noted to play a prominent role during infective exacerbations. In <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>, <i>H influenzae</i> was isolated from 69% of sputum samples collected during acute exacerbations, and from 33% and 44% in the placebo and vaccine groups, respectively in <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a> (this difference was not significant). <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a> and <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> did not discuss the bacterial carriage specifically during acute exacerbations. It is notable that <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> found that the numbers of acute infective exacerbations were higher (P = 0.011) in participants in the vaccine group from whose sputum <i>H influenzae</i> was isolated either before or during an acute episode. </p> <p><a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> noted that of the sputum samples that grew a respiratory pathogen, <i>H influenzae</i> played a role, but not a prominent one, accounting for only 6%; 6.2% grew <i>S pneumoniae</i> , 7.5% <i>Moraxella catarrhalis,</i> and 6.0% <i>P aeruginosa</i>. <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a> noted that during the six‐month trial, the proportion of <i>H parainfluenzae</i> infections was between 57% and 89% greater than the proportion of <i>H influenzae</i> infections during the same time period across both groups. This poses the question of the clinical impact of treating <i>H influenzae</i> as prophylaxis, as the background carriage rates may reflect the rates in acute exacerbation. The remaining four studies of this meta‐analysis did not report whether other pathogens were cultured alongside <i>H influenzae</i>; it is worthwhile to consider that acute (infective) exacerbations of COPD may be in part due to a host of multiple organisms rather than a single isolate. </p> <p>The population studied in the Papua New Guinea study raises concerns about the potential applicability of the results to the COPD patient in high‐income countries (<a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>). Asymptomatic background carriage rates were high: 57% of routine sputum samples isolated <i>H influenzae</i> (37% isolated <i>S pneumoniae</i> and 11% demonstrated <i>H parainfluenzae</i>). There were also some significant methodological problems in this study, with 53 out of 362 samples needing to be excluded due to betel nut consumption or epithelial contamination. </p> </section> <section id="CD010010-sec-0079"> <h4 class="title">Numbers of prescriptions for antibiotics and corticosteroids in the trial</h4> <p>Antibiotics were prescribed in four out of the six clinical trials (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>), but this was not necessarily an effective outcome measure that correlated with disease progression or severity. Given the high variability and lack of consistency concerning antibiotic course administration and measurements, we could not perform a truly uniform assessment and comparison amongst the trials. Whilst the three studies pooled for quantitative analysis appeared to indicate slightly more prescriptions having been issued to participants in the placebo group (RR 1.81; 95% CI 1.35 to 2.44; P &lt; 0.001) (<a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>), this conclusion remains unconvincing. There was also no reported follow‐up regarding what effect antibiotics had on participants (e.g. if there was resolution of symptoms or reduction in carriage levels). </p> <p>The application of current therapeutic guidelines in the trials was similarly questionable, with the intentions and protocols for prescribing antibiotics largely unclear and not reported in their methods. It is understood that at least half of patients with chronic bronchitis and COPD are persistently colonised with <i>H influenzae</i> , <i>S pneumonia,</i> or <i>M catarrhalis</i> (<a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>), hence a positive sputum culture that is not necessarily indicative of an acute infection and subsequent antibiotic prescription (in <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>, 48% in the vaccinated group and 50% in the placebo group had a validated positive sputum culture). Normally in exacerbations of COPD, sputum cultures would only be done if there was a failure of response to treatment or if the patient had repeated bacterial exacerbations within several months. Nonetheless, these organisms may be responsible for more severe exacerbations, for which antibiotics have been shown to be of benefit. The aim of treatment with antibiotics in acute exacerbations should be to alleviate symptoms and reduce the volume of sputum rather than total elimination of colonising organisms. </p> <p>None of the trials specified the class of antibiotic therapy used or explore sensitivities. This is important given that currently only amoxicillin and doxycycline regimens have been shown to be superior over other antibiotic classes such as macrolides, which fail to suppress <i>H influenzae</i> (<a href="./references#CD010010-bbs2-0022" title="LongoD , FauciA , KasperD , HauserS , JamesonJ , LoscalzoJ . Harrison's Principles of Internal Medicine. 18th Edition. Vol. 1 &amp; 2, New York: McGraw‐Hill, 2011. ">Longo 2011</a>). </p> <p>Two trials measured the addition of corticosteroid use as an outcome (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> reported a median duration of five treatment days (minimum 0, maximum 313) in the vaccine group and 10 days (minimum 0, maximum 306) in the placebo group. <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> reported a total 56% reduction in the proportion with acute exacerbations with corticosteroid treatment across both vaccine and placebo arms of their trial; further analysis by the authors to see if it reduced subsequent recurrent exacerbations showed that there was a 33% reduction in the vaccine group compared to a 55% reduction in the placebo group, with an average of about 40% reduction for recurrent exacerbations. </p> <p>Even though two studies reported the use of corticosteroids for the treatment of acute exacerbations, this does not preclude participants from receiving corticosteroids prior to and during the studies. Many of the participants were admitted to hospital during the study period and were likely to have received a short course of systemic corticosteroids (in <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> and <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>, a total of 83 participants in the vaccinated groups and 56 in the placebo groups). Short (not extended) courses of oral prednis(ol)one or intravenous hydrocortisone have been shown to shorten the duration of hospital admission and hasten return to previous lung function and stable symptom control and are routinely used for severe exacerbations of COPD (<a href="./references#CD010010-bbs2-0022" title="LongoD , FauciA , KasperD , HauserS , JamesonJ , LoscalzoJ . Harrison's Principles of Internal Medicine. 18th Edition. Vol. 1 &amp; 2, New York: McGraw‐Hill, 2011. ">Longo 2011</a>). </p> </section> <section id="CD010010-sec-0080"> <h4 class="title">Hospitalisations</h4> <p>Two studies reported hospitalisations (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a>). Information in the studies regarding participant hospitalisations was limited and in different units of measurement therefore not allowing the 2 studies to be meta‐analysed together; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> presented their data has a rate ratio, whereas <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> presented data dichotomously. Further consistent data parameters, such as length of hospital stay and intensive care versus general ward admission, would have been necessary for a more complete analysis. </p> <p>In the <a href="./references#CD010010-bbs2-0006" title="PhilipsM , TandonM , WartererG , DunkleyM , ClancyR . HI‐164 an oral vaccine to non‐typeable haemophilus influenzae reduces antibiotic use respiratory exacerbations and hospitalisations in patients with COPD. European Respiratory Journal2007;30:224. TandonM , PhillipsM , WatererG , DunkleyM , ComansP , ClancyR . Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest2010;137(4):805‐11. ">Tandon 2010</a> study, admissions to hospital were high in the placebo group, with 11 admissions compared to one admission in the vaccination group. This demonstrates that the chance of hospital admission for those receiving the NTHi vaccine was reduced by 90% (P = 0.05). <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> noted a similar outcome, showing a 50% acute exacerbation event reduction in hospital admissions following an acute exacerbation in the vaccine group (P = 0.047). </p> </section> <section id="CD010010-sec-0081"> <h4 class="title">Any associated adverse side effects from the NTHi vaccination, measurable from symptomology and participant reports </h4> <p>There was no clear definition of what constituted an adverse effect and therefore no consistency between the studies' reporting of adverse events. For example, <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> included increase of dyspnoea and cough as an adverse event, while <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> reported mortality as a severe adverse event. None of the trials reported methods used for monitoring adverse events. There is thus potentially an under‐reporting of less severe side effects. We could reach no clear comparisons or conclusions regarding any association between adverse effects and therapeutic effect. The adverse effects presented in the trials may well have been attributable to the significant comorbidity of the participant rather than to the vaccine. To discern whether these symptoms or adverse effects were true side effects of the vaccine or whether they were sequelae of the participant's disease process was not possible in this review due to the lack of primary study data. </p> </section> <section id="CD010010-sec-0082"> <h4 class="title">Quality of life</h4> <p>Only two studies reported quality of life (QoL) measures (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a>), and these trials used different measurement tools, limiting the comparisons that could be made between the results. It is also notable that, by nature, the measurement of quality of life is subjective and difficult to quantify; neither study provided further data and information regarding which aspect of QoL was most improved. Nonetheless, both trials reported at least a two‐point improvement in participant QoL in the vaccinated group versus the placebo group. Improvement in QoL was based on overall clinical condition assessed at the start of the trial and at set points during the trial. These intervals differed slightly between the two trials, with <a href="./references#CD010010-bbs2-0005" title="TandonMK . Double‐blind control trial of oral immunisation trial with killed Haemophilus influenzae (Bronchostat) in elderly chronic obstructive airway disease patients. Australian and New Zealand Journal of Medicine Supplement1990;19(5):650. TandonMK , GebskiV . A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand Journal of Medicine1991;21(4):427‐32. ">Tandon 1991</a> measuring at six months and <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> measuring at three and six months. <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> did not provide data on QoL for participants over 65 years of age. </p> </section> </section> <section id="CD010010-sec-0083"> <h3 class="title" id="CD010010-sec-0083">Overall completeness and applicability of evidence</h3> <p>Although the numbers and sizes of the studies were low, all of the trials included participants with established COPD or chronic bronchitis. <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a> was the only study with sufficient sample size to conduct subgroup analyses assessing the effects of the vaccine in people less than 65 years of age. The majority of studies (with the exception of <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>, which was conducted in Papua New Guinea) were conducted in an Australian population. However, trial length and follow‐up periods varied from three to 12 months among the trials. The majority of the studies administered the HI‐164 oral vaccine enteric‐coated tablets (two per day), each of which contained 45 mg active substance of formalin‐inactivated NTHi, which was compared with enteric‐coated placebo tablets (with the exception of <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>, which used a sodium tauroglycocholate substitute for the placebo). All studies had comparable objectives assessing the effect of the vaccine on acute COPD exacerbations. </p> <p>We consider the results of this review to be applicable to people with established COPD. </p> </section> <section id="CD010010-sec-0084"> <h3 class="title" id="CD010010-sec-0084">Quality of the evidence</h3> <p>Overall, the methodological quality of the trials was acceptable, with most trials reporting methods of random sequence generation and allocation concealment sufficiently to assess them as adequate. The greatest limitation of the included studies was that of the six trials, one was by far the largest in terms of included population. The smaller studies were underpowered, and even when pooling the five smaller studies, their weighting was inferior to that of the one larger trial (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>). </p> <p>The assessment of primary outcomes of acute exacerbations was carried out through respiratory questionnaires, which are subjective, instead of using objective measures such as spirometry. Secondary outcomes such as <i>H influenzae</i> colonisation and antibiotic use are more objective but may be difficult to measure. Studies had low rates of loss to follow‐up, and attrition rates were low and equal in both arms of the trials. </p> <p>We found a moderate degree of heterogeneity in this meta‐analysis, specifically in the outcome measuring the number of acute exacerbations of COPD (I<sup>2</sup> = 57%, P = 0.04). <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> appears to contribute most to the heterogeneity; its exclusion from the analysis dramatically reduces heterogeneity (I<sup>2</sup> = 24%, P = 0.26) and can likely be attributed to the study's reported result of only one exacerbation in the vaccinated group. Nonetheless, the exclusion of <a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a> from the meta‐analysis did not appear to have a significant impact on the overall result, given the small study size of approximately 30 participants and the robustness of the data sourced from the remaining studies. </p> </section> <section id="CD010010-sec-0085"> <h3 class="title" id="CD010010-sec-0085">Potential biases in the review process</h3> <p>Two review authors independently conducted all data selection and extraction, with a third review author acting as an arbiter, in order to minimise the risk of error and bias. One of the review authors (AC) was involved as an investigator in four of the six included trials (<a href="./references#CD010010-bbs2-0001" title="ClancyR , CrippsA , Murree‐AllenK , YeungS , EngelM . Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet1985;2(8469‐70):1395‐7. ClancyR , CrippsA , PangG , YeungS , Murree‐AllenK . The paradox of immunisation against Haemophilus influenzae‐related endobronchitis: protection restricted to ingestion of 'non‐adjuvenated' vaccine. Advances in Experimental Medicine and Biology1987;216b:1759‐64. ">Clancy 1985</a>; <a href="./references#CD010010-bbs2-0002" title="ClancyRL , CrippsAW . Protection against recurrent acute bronchitis after oral immunisation with killed Haemophilus influenzae. Medical Journal of Australia1990;152(8):413‐6. ">Clancy 1990</a>; <a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>; <a href="./references#CD010010-bbs2-0004" title="LehmannD , CoakleyKJ , CoakleyCA , SpoonerV , MontgomeryJ , MichaelA , et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. American Review of Respiratory Disease1991;144(2):324‐30. ">Lehmann 1991</a>), but not involved in the data extraction and analysis in the review in order to reduce interpretation bias. </p> <p>It is possible that despite extensive searching we may have missed a trial. However, this is very unlikely as one of the review authors is a world‐renowned expert in the field and has consulted his extensive network to search for additional unpublished data. We are therefore confident that we have captured all available evidence in this review. </p> </section> <section id="CD010010-sec-0086"> <h3 class="title" id="CD010010-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>This is an update of a previously withdrawn Cochrane review of the same title (<a href="./references#CD010010-bbs2-0033" title="FoxwellAR , CrippsAW , DearKBG . Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD001958.pub2] ">Foxwell 2006</a>). The authors of the previous review concluded that the vaccine was efficacious in reducing 20% to 30% of acute exacerbations in COPD patients and supported its use clinically. They also concluded that there was a need for larger clinical trials to assess longer‐term prognosis. Since publication of the previous review a new trial with a substantially larger population has been published (<a href="./references#CD010010-bbs2-0003" title="ClancyR , DunkleyM . Age dependent protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Newcastle University and Bioxyne Pty Ltd. ClancyR , DunkleyM , SocklerJ , McDonaldC . Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal Medicine Journal2016;46(4):684‐93. [DOI: 10.1111/imj.13072] ">Clancy 2016</a>), and we have been able to include this in our updated meta‐analysis. As a result of the inclusion of this large trial, the validity of the review has increased and the conclusions have changed substantially. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010010-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Inclusion of trials flow diagram." data-id="CD010010-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Inclusion of trials flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Primary outcomes, outcome: 1.1 Exacerbations (number of exacerbations/person/year).Refer to for Overall rate estimates of acute exacerbations across included studies." data-id="CD010010-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Primary outcomes, outcome: 1.1 Exacerbations (number of exacerbations/person/year). </p> <p>Refer to <a href="#CD010010-tbl-0002">Table 1</a> for <i>Overall rate estimates of acute exacerbations across included studies</i>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Primary outcomes, outcome: 1.2 Mortality (deaths during trial period)." data-id="CD010010-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Primary outcomes, outcome: 1.2 Mortality (deaths during trial period). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Prescriptions (number of courses/person/year).Refer to for Overall rate estimates of antibiotic prescriptions across included studies." data-id="CD010010-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Prescriptions (number of courses/person/year). </p> <p>Refer to <a href="#CD010010-tbl-0003">Table 2</a> for <i>Overall rate estimates of antibiotic prescriptions across included studies</i>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Adverse events (number of adverse events/person/year).Refer to for Overall rate estimates of adverse events across included studies." data-id="CD010010-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Adverse events (number of adverse events/person/year). </p> <p>Refer to <a href="#CD010010-tbl-0004">Table 3</a> for <i>Overall rate estimates of adverse events across included studies</i>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcomes, Outcome 1 Exacerbations (number of exacerbations/person)." data-id="CD010010-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Primary outcomes, Outcome 1 Exacerbations (number of exacerbations/person).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#CD010010-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcomes, Outcome 2 Mortality (deaths during trial period)." data-id="CD010010-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Primary outcomes, Outcome 2 Mortality (deaths during trial period).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#CD010010-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Secondary outcomes, Outcome 1 Prescriptions (number of courses/person/year)." data-id="CD010010-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Secondary outcomes, Outcome 1 Prescriptions (number of courses/person/year).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#CD010010-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010010-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/urn:x-wiley:14651858:media:CD010010:CD010010-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_t/tCD010010-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Secondary outcomes, Outcome 2 Adverse events (number of adverse events/person)." data-id="CD010010-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Secondary outcomes, Outcome 2 Adverse events (number of adverse events/person).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#CD010010-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/media/CDSR/CD010010/image_n/nCD010010-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010010-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Haemophilus influenzae oral vaccination for prevention of acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><i>Haemophilus influenzae</i> oral vaccination for prevention of acute exacerbations of chronic bronchitis and COPD </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (&gt; 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis </p> <p><b>Settings:</b> community and outpatients </p> <p><b>Intervention:</b> oral monobacterial vaccination with killed NTHi </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> <p><b><i>Not vaccinated</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> <p><b><i>NTHi oral vaccinated</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute exacerbations</b> </p> <p>(number of exacerbations/person/year)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2.111 exacerbations per person/year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.668 exacerbations</b> <br/> <b>per person/year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p><b>(0.57 to 1.10)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>557<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Despite an absolute estimated decrease in the rate of exacerbations in the vaccinated group, the result is negligible (95% CI crosses 1.00) and not statistically significant (P = 0.16) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p>(deaths during trial period)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (15 to 88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.62</b> </p> <p><b>(0.63 to 4.12)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Despite more absolute deaths occurring in the vaccinated group, the result is negligible (95% CI crosses 1.00) and not statistically significant (P = 0.31). Deaths were not necessarily attributed to the use of the vaccine </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carriage of NTHi</b> </p> <p><i>Not meta‐analysed</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to meta‐analyse the carriage levels of NTHi in participants as each trial reported this result using different units and tools of measurement. 4 trials showed no significant difference in carriage levels, while 2 trials showed a significant decrease in carriage levels in the vaccinated group compared with the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic prescriptions</b> </p> <p>(number of courses/person/year)</p> <p>**<i>Corticosteroids not meta‐analysed</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5.723</b> <br/> <b>prescriptions</b> <br/> <b>per person/year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3.162</b> <br/> <b>prescriptions</b> <br/> <b>per person/year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.81</b> </p> <p><b>(1.35 to 2.44)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Courses of antibiotics were found to be prescribed in the placebo group at a rate approximately 80% greater than in the vaccinated group (P &lt; 0.001) </p> <p>(Note that a RR &gt; 1.0 here indicates more antibiotics being prescribed to participants in the placebo group, i.e. RR 1.81 corresponds to an approximately 80% increased rate of antibiotic prescriptions when not receiving the vaccine. The placebo group is being compared to the vaccine group in this instance to attempt to demonstrate how many more antibiotics are required in those not vaccinated) </p> <p>**2<i>studies reported corticosteroid use, however due to differences in units of measurement, these results could not be meta‐analysed</i> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> <p>(number of participants hospitalised during trial period)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admissions was not meta‐analysed due to differing units of measurement by the 2 trials that reported this finding. Notwithstanding that pooling the data for the 2 trials would have yielded high heterogeneity. Hospital admissions were not necessarily attributable to the vaccine </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>(number of adverse events/person/year)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.319</b> <br/> <b>adverse events</b> <br/> <b>per person/year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.456</b> <br/> <b>adverse events</b> <br/> <b>per person/year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> </p> <p><b>(0.70 to 2.92)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484<br/> (5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Despite an estimated absolute increased rate of adverse events in the vaccinated group, the result is negligible (95% CI crosses 1.00) and not statistically significant (P = 0.61). Adverse events were not necessarily attributable to the vaccine </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Not meta‐analysed</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life was not meta‐analysed due to differing units of measurement, but was reported in 2 trials, which showed an improvement at 6 months in the vaccine group (scoring at least 2 points better than the placebo group; significance unknown) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval (CI)) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>N/A:</b> not applicable; <b>NTHi:</b> non‐typeable <i>Haemophilus influenzae</i>; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>One study had marked heterogeneity; most studies had a low number of participants; one study had significant attrition.<br/> <sup>2</sup>Mortality was not formally measured; five studies reported on deaths but none attributed to vaccine.<br/> <sup>3</sup>Only three studies recorded information on prescriptions; studies had a low number of participants; method of allocation concealment and randomisation was unclear in two of the studies.<br/> <sup>4</sup>Only two studies recorded information on hospitalisations; one study was significantly larger than the other.<br/> <sup>5</sup>Most studies had a low number of participants; one study may have had attrition bias; two studies had high risk of bias for randomisation and allocation concealment.<br/> <sup>6</sup>Meta‐analysis was not performed; inconsistent units of measurement used by studies, therefore not comparable. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Haemophilus influenzae oral vaccination for prevention of acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010010-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Rate estimates of acute exacerbations across included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Vaccinated</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> *Absolute rate difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 1985</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.256</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.272</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.016 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 1990</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.700 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.717</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.767</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.050 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lehmann 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.800</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.410 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.355</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.009 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.667</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.350</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.683 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall mean</b> </i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1.633</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2.111</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.478 (‐)</i> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Estimated rate of exacerbation calculated as number of exacerbations per person per year. </p> <p>Refer to <a href="./references#CD010010-fig-0006" title="">Analysis 1.1</a>: <i>Forest plot comparison and rate ratios for exacerbations</i>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Rate estimates of acute exacerbations across included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010010-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rate estimates of antibiotic prescriptions across included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Vaccinated</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> *Absolute rate difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 1990</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.700 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.806</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.388 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.180</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.020 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall mean</b> </i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>3.162</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>6.198</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>3.036 (‐)</i> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Estimated rate of antibiotic prescriptions calculated as number of antibiotic courses per person per year. </p> <p>Refer to <a href="./references#CD010010-fig-0008" title="">Analysis 2.1</a>: <i>Forest plot comparison and rate ratios for antibiotic prescriptions</i>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rate estimates of antibiotic prescriptions across included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010010-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Rate estimates of adverse events across included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Vaccinated</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> *Absolute rate difference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clancy 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.025</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.017 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lehmann 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.067</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.031</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.036 (+)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.032</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.212</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.180 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tandon 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.450</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.283 (‐)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall mean</b> </i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.319</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.430</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>0.111 (‐)</i> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Estimated rate of adverse events calculated as number of adverse events per person per year. </p> <p>Refer to <a href="./references#CD010010-fig-0009" title="">Analysis 2.2</a>: <i>Forest plot comparison and rate ratios for adverse events</i>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Rate estimates of adverse events across included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/full#CD010010-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010010-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations (number of exacerbations/person) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (deaths during trial period) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.63, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#CD010010-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010010-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Secondary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prescriptions (number of courses/person/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.35, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (number of adverse events/person) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.70, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010010.pub3/references#CD010010-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010010.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010010-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010010-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010010-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010010-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010010-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010010\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010010\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010010\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010010\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010010\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010010.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010010.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010010.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010010.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010010.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714970346"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010010.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714970350"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010010.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7baefebb9368',t:'MTc0MDcxNDk3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 